RibomicTSE:4591 +3.28%25 PS Ratio is 1,145.45 as of Jul. 01, 2026, which is 1320% above its 10-year median of 80.65. GuruFocus rates TSE:4591 with a GF Score™ of 25/100. The stock has 3 warning signs investors should review. Among 934 Biotechnology companies, Ribomic ranks worse than 95.93% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Ribomic's share price is 円63.00.
Ribomic's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円0.06. Hence, Ribomic's PS Ratio for today is 1,145.45.
Good Sign:
Ribomic Inc stock PS Ratio (=983.33) is close to 1-year low of 983.33.
The historical rank and industry rank for Ribomic's PS Ratio or its related term are showing as below:
TSE:4591'
s PS Ratio Range Over the Past 10 Years
Min: 35.36 Med: 80.65 Max: 2288.46
Current: 1145.45
During the past 13 years, Ribomic's highest PS Ratio was 2288.46. The lowest was 35.36. And the median was 80.65.
TSE:4591's PS Ratio is ranked worse than 95.93% of 934
companies
in the Biotechnology industry
Industry Median: 9.515
vs TSE:4591: 1145.45
Ribomic's Revenue per Sharefor the
six
months ended in Mar. 2026 was 円0.06.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円0.06.
Warning Sign:
Ribomic Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Ribomic was 15.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -69.50% per year.
During the past 13 years, Ribomic's highest 3-Year average Revenue per Share Growth Rate was 73.30% per year. The lowest was -73.80% per year. And the median was -34.70% per year.
Back to Basics: PS Ratio
Ribomic (TSE:4591) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Ribomic PS Ratio Related Terms
Ribomic PS Ratio Historical Data
* Premium members only.
The historical data trend for Ribomic's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ribomic's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ribomic PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ribomic's PS Ratio distribution charts can be found below:
* The bar in red indicates where Ribomic's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Ribomic's Share Price of today is 円63.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ribomic's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円0.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Ribomic (TSE:4591) has a PS Ratio of 1,145.45 as of Jul. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Ribomic and its competitors. This is 1320% above median its historical median of 80.65. Over the past decade, Ribomic's PS Ratio has ranged from 35.36 to 2,288.46. According to the industry distribution chart, Ribomic ranks #896 out of 934 companies in the Biotechnology industry, placing it in the top 95.9%.
Is Ribomic's PS Ratio too high?
Ribomic's current PS Ratio of 1,145.45 is 1320% above median its 10-year median of 80.65. Over the past 10 years, this metric has ranged from a low of 35.36 to a high of 2,288.46. The Biotechnology industry median PS Ratio is 9.52. Ribomic's value of 1,145.45 is 11938.4% above this industry median. Based on the distribution chart, Ribomic ranks #896 out of 934 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ribomic has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Ribomic's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ribomic ranks #896 out of 934 companies for PS Ratio. This places Ribomic in the lower half of its industry. The industry median PS Ratio is 9.52. Ribomic's value of 1,145.45 is 11938.4% above this benchmark. Historically, Ribomic's own PS Ratio has ranged from 35.36 to 2,288.46 over the past decade. While the company's 10-year median is 80.65 vs. the industry median of 9.52, Ribomic has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ribomic's current PS Ratio of 1,145.45 is 11938.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Ribomic and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ribomic's current PS Ratio is 1,145.45, which is 1320% above median its own 10-year median of 80.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ribomic stock overvalued right now?
Ribomic (TSE:4591) has a current PS Ratio of 1,145.45. The current PS Ratio is 1,145.45, which is 1320% above median its 10-year median of 80.65 and 11938.4% above the Biotechnology industry median of 9.52. Ribomic's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Ribomic (TSE:4591), the current PS Ratio is 1,145.45 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ribomic Inc is a biopharmaceutical venture company based in Tokyo. The company is developing molecular targeted pharmaceutical drugs using RNA aptamers with its unique and advanced platform technologies, the RiboART System.
25GF Score
Get the complete analysis for TSE:4591
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4591 has been successfully added to your 
